Recombinant Interleukin-2 (IL-2)

Recombinant human IL-2 is a cytokine growth factor stimulating T-cell proliferation for cancer immunotherapy. It is an unmixed immunological product under HTS 3002.13.0090, explicitly covered by chapter notes for interleukins regulating immune processes. Supplied in bulk for pharmaceutical compounding.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

2937.90.90Same rate: Free

If derived from heading 2937 products like nucleosides

Chapter notes exclude 2937 goods from immunological definition.

3002Same rate: Free

If specifically human blood antisera

Distinction from other fractions; antisera have separate subheading.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Include potency assay certificates (IU/mg) to verify biological activity and therapeutic grade

Declare under 'human blood fractions' if applicable, but specify biotech origin to avoid animal blood confusion

Related Products under HTS 3002.13.00.90

Unmixed Monoclonal Antibody Bevacizumab

Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for therapeutic use in cancer treatment. It falls under HTS 3002.13.0090 as an unmixed immunological product not put up in measured doses or retail packaging, directly involved in regulating immunological processes. This classification applies to bulk biotech-derived antibodies for further pharmaceutical processing.

Bulk Rituximab Immunological Product

Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells, used in lymphoma and autoimmune disease therapy. Classified under HTS 3002.13.0090 as an unmixed immunological product obtained via biotechnological processes, supplied in bulk for formulation. It regulates immunological processes as defined in chapter notes.

Unmixed Infliximab Biosimilar

Infliximab biosimilar is a monoclonal antibody binding TNF-alpha, used for inflammatory conditions like rheumatoid arthritis. HTS 3002.13.0090 covers it as an unmixed, biotech-derived immunological product not in retail form. It qualifies per chapter notes as a protein regulating immunological processes.

Bulk Trastuzumab Emtansine Conjugate

Trastuzumab emtansine is an antibody-drug conjugate (ADC) with monoclonal antibody linked to chemotherapy agent for HER2-positive breast cancer. Classifies as unmixed immunological product in HTS 3002.13.0090 per notes covering antibody conjugates. Bulk form excludes retail packaging.

Adalimumab High-Concentration Solution

Adalimumab is a fully human monoclonal antibody against TNF for autoimmune diseases like psoriasis. As an aqueous solution of unmixed product, it qualifies under HTS 3002.13.0090 per chapter notes treating dissolved unmixed products similarly. Bulk for further dilution.

Bulk Pembrolizumab

Pembrolizumab is a PD-1 inhibitor monoclonal antibody for immuno-oncology applications. Classifies in HTS 3002.13.0090 as unmixed biotech immunological product regulating immune checkpoint processes. Not for retail sale.